Literature DB >> 16236661

Polypharmacy and possible drug-drug interactions among diabetic patients receiving home health care services.

Ibrahim A Ibrahim1, Eunjeong Kang, Kathryn H Dansky.   

Abstract

OBJECTIVES: In this study, we examined the drug regimens of diabetic patients receiving home health care services to measure the prevalence of polypharmacy and to assess the likelihood of drug-drug interactions, a consequence of polypharmacy.
DESIGN: The sample consisted of 139 diabetic patients who received home health care services from one home health agency in a large mid-Atlantic city. The data were collected from March 1, 1998 to September 30, 1999. Information regarding medications was collected by the home health nurse during the initial home visit and was recorded on the medication sheet in the patient's clinical record. Any changes in medications were noted on the medication sheets.
METHODS: We identified all systemic medications prescribed for 139 home health patients. To assess drug-drug interactions, we used Micromedex formulary DRUG-REAX System. OUTCOMES: We calculated (1) the number of systemic medications taken, and (2) the number of possible severe, moderate, and mild drug-drug interactions.
RESULTS: We found that the average number of medications taken was 8.9 (SD 3.4) prescribed medications per day. Our results show that 38.8% of the patients in the sample could potentially be subject to at least one severe drug-drug interaction. Nearly all of the patients (92.8%) were at risk for moderate drug-drug interactions, and 70.5% could have mild drug- drug interactions.
CONCLUSION: We conclude that polypharmacy is a concern for home health care patients with diabetes and the potential for drug-drug interactions is substantial. Our results indicate that the drug regimens of diabetic patients should be monitored systematically to avoid adverse events such as hospitalization. Family practitioners and home health care takers are in a unique position to identify polypharmacy and to modify drug regimens.

Entities:  

Mesh:

Year:  2005        PMID: 16236661     DOI: 10.1300/J027v24n01_07

Source DB:  PubMed          Journal:  Home Health Care Serv Q        ISSN: 0162-1424


  7 in total

1.  Interaction risk with proton pump inhibitors in general practice: significant disagreement between different drug-related information sources.

Authors:  Gianluca Trifirò; Salvatore Corrao; Marianna Alacqua; Salvatore Moretti; Michele Tari; Achille P Caputi; Vincenzo Arcoraci
Journal:  Br J Clin Pharmacol       Date:  2006-07-06       Impact factor: 4.335

2.  A drug interactions elective course.

Authors:  Jennifer Trujillo
Journal:  Am J Pharm Educ       Date:  2009-07-10       Impact factor: 2.047

3.  Medications Associated With Geriatric Syndromes (MAGS) and Hospitalization Risk in Home Health Care Patients.

Authors:  Jinjiao Wang; Jenny Y Shen; Fang Yu; Yeates Conwell; Kobi Nathan; Avantika S Shah; Sandra F Simmons; Yue Li; Erika Ramsdale; Thomas V Caprio
Journal:  J Am Med Dir Assoc       Date:  2022-04-28       Impact factor: 7.802

4.  Polypharmacy and risk of antiretroviral drug interactions among the aging HIV-infected population.

Authors:  Carol Holtzman; Carl Armon; Ellen Tedaldi; Joan S Chmiel; Kate Buchacz; Kathleen Wood; John T Brooks
Journal:  J Gen Intern Med       Date:  2013-04-20       Impact factor: 5.128

5.  Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects.

Authors:  Helene Hausner; Julie Derving Karsbøl; Anders G Holst; Jacob B Jacobsen; Frank-Dietrich Wagner; Georg Golor; Thomas W Anderson
Journal:  Clin Pharmacokinet       Date:  2017-11       Impact factor: 6.447

Review 6.  Effects of Polypharmacy in Elderly Diabetic Patients: A Review.

Authors:  Sweta Kumari; Shraddha Jain; Sunil Kumar
Journal:  Cureus       Date:  2022-09-12

7.  Characteristics associated with polypharmacy in people with type 2 diabetes: the Dutch Diabetes Pearl cohort.

Authors:  S van Oort; F Rutters; M F Warlé-van Herwaarden; M T Schram; C D Stehouwer; C J Tack; E J Abbink; B H Wolffenbuttel; M M van der Klauw; J H DeVries; S E Siegelaar; E J Sijbrands; B Özcan; H W de Valk; B Silvius; M A Schroijen; I M Jazet; A J van Ballegooijen; J W J Beulens; P J Elders; C Kramers
Journal:  Diabet Med       Date:  2020-10-17       Impact factor: 4.359

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.